View
221
Download
0
Category
Preview:
Citation preview
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
1/18
nazan tuna, oguz karabay, mehmet yahyaoglu
Indian J of PharmacolAug 2011;43(4):437-40
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
2/18
introduction
Influenza virus is a segmented genome, negative polarity,enveloped RNA virus.
The virus caused major pandemics in 1918(H1N1), 1957(H2N2),
1968(H3N2) & more recently in feb 2009(H1N1).
Resistance was reported to amantadine and rimantadine .
During the last outbreak, the two neuraminidase inhibitors-oseltamivir and zanamivir, were used in the treatment.
They reduce the severity, duration of the disease and prevent
deaths.
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
3/18
Objectives
The study aimed to compare the efficacy and tolerability of
oseltamivir and zanamivir in the treatment of influenza
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
4/18
Inclusion criteria Fever 38C &the presence ofatleast of one of the following symptoms-
sorethroat, headache, myalgia, weakness, diarrhoea, nausea, vomiting,
cough, rhinorrhea and respiratory distress.
Initiated on either oseltamivir or zanamivir within the first 48h of
disease onset.
o Not receiving other drugs of palliation.
o Age group: 17-70 yrs.
o Who were diagnosed to be suffering from influenza.
o Pt. not requiring hospitalization.
o BMI < 30
o Non-pregnant females.
o Not with chronic diseases such as bronchial asthma.
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
5/18
Exclusion criteria
Pts who were tested negative negative for influenza infection onPCR testing.
Pts with chronic diseases like bronchial asthma
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
6/18
Study design Retrospective, randomized study.
Open labelled.
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
7/18
Methodology
Study duration- october 2009 and february 2010 duringpandemic period.
Institutional Ethics Committee- approved
Total- 136 pts records obtained.
Exclusion -56( lack of data, COPD, asthma, pneumonia)
Included 80 pts
Treatment :-
Oseltamivirtwice a day as 150mg(2x75mg) PO for 5 days Zanamivir- twice a day as 10mg(2x5mg) oral inhaler for 5 days
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
8/18
MethodologyTests :-
Healing criteria- time taken for axillary temp. to be normal.
decrease in myalgia.
loss of symptoms.
lack of complications. H1N1 PCR test from nasal swab ( only 8 pts received it)
ALT, AST, CBC, CRP, Urea, Creatinine, blood glucose and
cretinine kinase levels- Day0, Day2, DAY 5 Adverse events review from registered file information.
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
9/18
MethodologyStatistical evaluation:
For quantifiable variables- students t- test.
For categorical variables-X2 test.
P< 0.05 was considered statistically significant.
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
10/18
Results Demographical variables Table 1
M/F ratio-1.22 ( M-44, F- 36)
Average age- 30.811.6
Detected weakness in 97.5%
myalgia in 93.8%nausea in 46.3%
diarrhoea in 23.8%
Laboratory values-Table 3
Avg baseline WBC value- 7.3K/L in oseltamivir group6.4K/L in zanamivir group
Avg urea value- 22mg/dl- in both group
On reassessing parameters on D2 & D5- no significant diff.
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
11/18
Results
Efficiency values of oseltamivir & zanamivir-Table 2Fever Defervescence- 50.4hrs for O, 43.2hrs for Z
Disappearance of symptoms- 157.2hrs for O, 163.2hrs for Z
Resumption of work period- 158.4hrs for O, 145.2hrs for Z.
Adverse effects of oseltamivir & zanamivir- Table 4
Drowsiness- 37.5% in O, 27.5% in Z
Nausea- 25% in O, 15% in Z
No serious adverse effects in either group.
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
12/18
Discussion
H1N1 virus is considered to be resistant to M2 inhibitors( amantadine & rimantadine) while it is sensitive to
neuraminidase inhibitors ( oseltamivir and zanamivir)
Neuraminidase inhibitors, when used within the first 48hrs of the
the disease, not only reduced infectivity but also reduced the
duration of symptoms and mortality.
In this study, no significant difference was seen between 2drugs.
Fever is more rapidly resolved with Zanamivir but the incidence of
drowsiness(37.5%) was more when compared to
Oseltamivir(22.5%)
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
13/18
Discussion
Other adverse events include nausea ( O-25%, Z-15%), psychiatricproblems (O-7.5%, Z- 5%)
Respiratory distress was not found with O but was seen in Z.
Zanamivir has low bioavailability. However it is concentrated in
the oropharynx, respiratory airways and lungs.
Zanamivir should be used cautiously in pts with underlying
respiratory tract diseases.
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
14/18
Conclusion Zanamivir and oseltamivir were found to have similar efficacy
in terms of symptom relief & duration to resume work.
Temp. normalization was more rapid in pts using Zanamivir.
Neither drug has serious adverse effects.
However, pts. Who used Zanamivir suffered from respiratorydisease more often.
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
15/18
Merits randomized study
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
16/18
Demerits
Retrospective study Not blinded
Single centric
Less sample size
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
17/18
Limitations
7/28/2019 Comparision of Efficacy and Safety of Oseltamivir And
18/18
Is the title suitable for the study done?
Is the study hypothesis presented clearly? Is the review of literature appropriate & adequate?
Comment on the clarity & appropriateness of methodology.
Comment on the statistical analysis done.
Does the discussion extend support to the hypothesis beingtested?
Does the study add to the current knowledge?
Are limitations of the study discussed? Conflict of interest.
Overall impression of the paper.
Critique of the paper
Recommended